Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample

Schizophrenia Research

Volumn 121, Issue 1-3, 2010, Pages 207-212

  Diaz, Francisco J ^a   Pérez Iglesias, Rocío ^b,c   Mata, Ignacio ^b,c   Martínez Garcia, Obdulia ^b,c   Vázquez Barquero, José L ^b,c   de Leon, Jose ^d   Crespo Facorro, Benedicto ^b,c  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d M Hlth Res Ctr at E State Hosp   (United States)

Author keywords

C reactive protein; Haloperidol; Metabolic syndrome; Olanzapine; Risperidone; Schizophrenia; Smoking

Indexed keywords

C REACTIVE PROTEIN; HALOPERIDOL; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SMOKING; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; BODY MASS; DOUBLE BLIND PROCEDURE; IMMUNOASSAY; LONGITUDINAL STUDY; METABOLISM; PROCEDURES; PSYCHOTIC DISORDERS; STATISTICAL MODEL; TIME;

ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; HUMANS; IMMUNOASSAY; LINEAR MODELS; LIPOPROTEINS, HDL; LONGITUDINAL STUDIES; PSYCHOTIC DISORDERS; TIME FACTORS;

EID: 77955058549     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.06.002     Document Type: Article

References (22)

1. Akanji A.O., Ohaeri J.U., As-Shammri S., Fatania H.R. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 2009, 169:56-61.
2. Backes J.M., Howard P.A., Moriarty P.M. Role of C-reactive protein in cardiovascular disease. Ann. Pharmacother. 2004, 38:110-118.
3. Blasco-Fontecilla H., Baca-Garcia E., de Leon J. Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade. Schizophr. Res. 2010, 119:160-163.
4. Carrizo E., Fernández V., Quintero J., Connell L., Rodríguez Z., Mosquera M., Acosta A., Baptista T. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr. Res. 2008, 103:83-93.
5. de Leon J., Diaz F.J. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr. Res. 2007, 96:185-197.
6. de Leon J., Susce M.T., Johnson M., Hardin M., Pointer L., Ruaño G., Diaz F.J. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 2007, 92:95-102.
7. de Leon J., Susce M.T., Pan R.M., Wedlund P.J., Orrego M.L., Diaz F.J. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007, 40:93-102.
8. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA 2002, 287:356-359.
9. Lavie C.J., Milani R.V., Verma A., O'Keefe J.H. C-reactive protein and cardiovascular diseases - is it ready for primetime?. Am. J. Med. Sci. 2009, 338(6):486-492.
10. Maes M., Delante J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., Scharpé S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997, 66:1-11.
11. Mathieu P., Lemieux I., Despres J.P. Obesity, inflammation and cardiovascular risk. Clin. Pharmacol. Ther. 2010, 87:407-416.
12. Meyer J.M., Stahl S.M. The metabolic syndrome and schizophrenia. Acta Psychiatr. Scand. 2009, 119:4-14.
13. Meyer J.M., McEvoy J.P., Davis V.G., Goff D.C., Nasrallah H.A., Davis S.M., Hsiao J.K., Swartz M.S., Stroup T.S., Lieberman J.A. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. Biol. Psychiatry 2009, 66:1013-1022.
14. Migliardi G., Spina E., D'Arrigo C., Gagliano A., Germanò E., Siracusano R., Diaz F.J., de Leon J. Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1496-1501.
15. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl 1):1-93.
16. Pearson T.A. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am. J. Cardiol. 2004, 94:4F-8F.
17. Pelayo-Terán J.M., Pérez-Iglesias R., Ramírez-Bonilla M., González-Blanch C., Martínez-García O., Pardo-García G., Rodríguez-Sánchez J.M., Roiz-Santiáñez R., Tordesillas-Gutiérrez D., Mata I., Vázquez-Barquero J.L., Crespo-Facorro B. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the PAFIP. Early Interv. Psychiatry 2008, 2:178-187.
18. Perez-Iglesias R., Crespo-Facorro B., Amado J.A., Garcia-Unzueta M.T., Ramirez-Bonilla M.L., Gonzalez-Blanch C., Martinez-Garcia O., Vazquez-Barquero J.L. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J. Clin. Psychiatry 2007, 68:1733-1740.
19. Perez-Iglesias R., Crespo-Facorro B., Martinez-Garcia O., Ramirez-Bonilla M.L., Alvarez-Jimenez M., Pelayo-Teran J.M., Garcia-Unzueta M.T., Amado J.A., Vazquez-Barquero J.L. Weight gain induced by haloperidol, risperidone and olanzapine after 1year: findings of a randomized clinical trial in a drug-naïve population. Schizophr. Res. 2008, 99:13-22.
20. Perez-Iglesias R., Mata I., Pelayo-Teran J.M., Amado J.A., Garcia-Unzueta M.T., Berja A., Martinez-Garcia O., Vazquez-Barquero J.L., Crespo-Facorro B. Glucose and lipid disturbances after 1year of antipsychotic treatment in a drug-naïve population. Schizophr. Res. 2009, 107:115-121.
21. StataCorp Stata: Release 11. Statistical Software 2009, StataCorp LP, College Station, TX.
22. Woodward M. Epidemiology: Study Design and Data Analysis 2006, Chapman & Hall/CRC, Boca Raton. Second Edition.